Originally published 2020-11-29.

At the end of November 2020, NHS hospitals in England were told to get ready to start giving Covid-19 vaccinations within days, even before any vaccine had been approved. The plan, first reported by The Guardian on 27 November, centred on the Pfizer/BioNTech vaccine, with hospital staff and the over-80s expected to go first. It happened almost exactly as predicted: UK regulators authorised the vaccine on 2 December, and on 8 December 2020 a 90-year-old woman in Coventry became the first person in the world to receive it outside a clinical trial.
Below is how those preparations worked, why this particular vaccine forced hospitals to the front of the queue, how the Oxford vaccine fitted in, and what came next.
The instruction to hospitals
NHS sources told The Guardian that hospital trusts had been asked to be ready to receive their first deliveries in early December, with some given 7 December as a likely date. At that point the Medicines and Healthcare products Regulatory Agency (MHRA) had not yet given its approval, so the instruction was about readiness, not a firm start date: freezers, staff rotas, booking systems and consent forms all had to be in place in case the green light came quickly.
The urgency made sense. The winter second wave was building, hospitals were filling up again, and the government wanted to move the moment the regulator was satisfied.
Why the Pfizer vaccine went to hospitals first
The Pfizer/BioNTech vaccine uses messenger RNA, which is fragile. For long-term storage and transport it had to be kept at between minus 60 and minus 80 degrees Celsius, far colder than a normal medical freezer. Once thawed and kept in an ordinary fridge, the rules at the time allowed only about five days before it had to be used. Larger hospitals had the ultra-cold freezers and the staff to manage that; most GP surgeries and care homes did not.
That created a practical dilemma. Ministers had wanted to start with care home residents, who were dying in large numbers, but moving trays of vaccine out of hospitals and splitting them into small batches was difficult under the early rules. One hospital director summed it up to The Guardian:
"Once the vaccine gets to us it can't be used in the community, so only NHS staff will be able to have it, at least initially."
Hospital leaders expected that health workers on site would be among the first vaccinated simply because they were there when the doses arrived. In practice the first patients were older people already in hospital or attending outpatient clinics, alongside care home staff who could travel to a hospital hub.
How many doses, and how effective
The final trial analysis published on 18 November 2020 showed the Pfizer/BioNTech vaccine was about 95 percent effective at preventing symptomatic Covid-19. The UK had ordered 40 million doses, enough for 20 million people at two doses each, and the first batch delivered was 800,000 doses. Reports at the time suggested about four million might arrive before the end of 2020; supply in practice was slower.
Regulators had said in advance that a vaccine would need to show at least around 50 percent efficacy to be considered. The first results from Pfizer/BioNTech and from Moderna, both above 90 percent, far exceeded that bar and surprised many scientists.
Moderna's storage advantage
Moderna's vaccine, built on similar technology, was easier to handle: it could be kept at around minus 20 degrees Celsius, the temperature of a standard freezer, and for up to 30 days in a fridge. It was not approved in the UK until January 2021.
The Oxford vaccine and its dosing question
The UK government had pinned great hopes on the vaccine developed by the University of Oxford with AstraZeneca. It had secured access to the first 100 million doses, enough in principle to cover the whole adult population, and the vaccine could be stored in a normal fridge, which made it far easier to deliver through GP surgeries and pharmacies.
The interim results announced on 23 November 2020 were more complicated than Pfizer's. The headline efficacy of 70 percent combined two groups: about 62 percent in volunteers who received two full doses, and about 90 percent in a smaller group who, because of a dosing mix-up, got a half dose followed by a full dose. Scientists questioned whether the two groups should be pooled, and AstraZeneca agreed to run a further trial. These were legitimate questions about the analysis, not evidence that the vaccine was unsafe.
The MHRA approved the Oxford vaccine on 30 December 2020, and the first doses outside trials were given on 4 January 2021. It went on to become one of the most widely used vaccines in the world.
Who was first in line
Priority was set by the Joint Committee on Vaccination and Immunisation (JCVI), which ranked groups mainly by their risk of dying from Covid-19. The very top of the list was residents of care homes for older adults and their carers, followed by people aged 80 and over and frontline health and social care workers. After that, the order moved down through age bands, with people who had serious underlying conditions placed alongside older groups.
Age came first because it was by far the strongest predictor of severe illness. Anyone unsure whether a condition put them in a priority group was advised to talk to their GP or doctor.
What happened next
On 2 December 2020 the UK became the first country to authorise the Pfizer/BioNTech vaccine for emergency use. Six days later, on what newspapers called "V-Day", Margaret Keenan, 90, received the first jab at University Hospital in Coventry at 6.31 in the morning. Vaccinations began only in hospital hubs because of the storage rules, then spread to GP-led sites and, as handling guidance was relaxed, to care homes.
With the Oxford vaccine approved at the end of December, the programme sped up sharply in early 2021, reaching tens of millions of people within months.
Was Covid going to disappear?
Even in 2020 most experts did not expect vaccines to wipe the virus out. Covid-19 spreads easily, infects animals as well as people and keeps producing new variants, so the realistic goal was to turn it into an endemic illness that causes far fewer deaths and hospital admissions. That is broadly what happened: the virus still circulates, but vaccination and previous infection mean it is much less deadly for most people than it was in that first winter.
Sources: The Guardian, 27 November 2020 (original report); Al Jazeera, 8 December 2020: UK rolls out vaccine, 90-year-old woman first in line; Wikipedia: Pfizer–BioNTech COVID-19 vaccine; Wikipedia: Oxford–AstraZeneca COVID-19 vaccine; Wikipedia: Moderna COVID-19 vaccine.

COMMENTS